Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 11/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20436589 | 0.90 | ADORA2A (0.51) | ADORA2AADORA2BCYP19A1ADORA1KLKB1 | |
| SCHEMBL20436595 | 0.90 | ADORA2A (0.62) | ADORA2AADORA2BROCK2GSK3BAURKB | |
| SCHEMBL20436604 | 0.88 | ADORA2A (0.51) | ADORA2AADORA2BCYP19A1ADORA1KLKB1 | |
| SCHEMBL20416780 | 0.88 | ADORA2A (0.49) | ADORA2AADORA2BCYP19A1 | |
| SCHEMBL20436598 | 0.88 | ADORA2A (0.49) | ADORA2AADORA2BCYP19A1ADORA1KLKB1 | |
| SCHEMBL30401218 | 0.88 | ADORA2A (0.49) | ADORA2AADORA2BCYP19A1 | |
| SCHEMBL20401354 | 0.86 | ADORA2A (0.52) | ADORA2AADORA2BCYP19A1 | |
| SCHEMBL30401330 | 0.86 | ADORA2A (0.52) | ADORA2AADORA2BCYP19A1 | |
| SCHEMBL20401295 | 0.85 | TEK (0.51) | ADORA2AADORA2BCYP19A1 | |
| SCHEMBL30402264 | 0.85 | TEK (0.51) | ADORA2AADORA2BCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ADORA2B 2/4885ROCK2 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.